Novavax, Inc.
NVAXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeNovavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and. Valued at $1.60B, NVAX is a small-cap name in its sector. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Market Cap
$1.60B
Beta
2.44
P/E (TTM)
—
P/E (Fwd)
-59.18
EPS (TTM)
$-1.58
EPS (Fwd)
$-0.16
ROE
—
ROA
-6.5%
Cash
$719.3M
Total Debt
$297.3M
Free CF
$153.4M
52W Change
11.5%
Annual Financials
Cash vs Debt
Where NVAX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NVAX finished 17.23% above its 150-day moving average ($9.23) and 17.86% above its 200-day moving average ($9.18). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NVAX overbought or oversold?
At the October 20, 2026 close, NVAX's RSI(14) was 50.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Novavax, Inc. holds $719.3M in cash against $297.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $153.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Revenue has been uneven over recent years, ranging from $1.60B to $1.12B.
Novavax, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NVAX.